Valuation: Clarity Pharmaceuticals Ltd

Market Cap 877M 613M 538M 501M 460M 863M 59.04B 5.95B 2.32B 29.03B 2.3B 2.25B 100B P/E 2026 *
-7.99x
P/E 2027 * -7.34x
Enterprise Value 716M 501M 440M 409M 375M 705M 48.2B 4.85B 1.9B 23.7B 1.88B 1.84B 81.93B EV / Sales 2026 *
-
EV / Sales 2027 * 886x
Free-Float
79.07%
Yield 2026 *
-
Yield 2027 * -
1 day-8.20%
1 week+1.29%
Current month+9.81%
1 month+15.20%
3 months-20.07%
6 months-32.08%
Current year-30.47%
1 week 2.17
Extreme 2.17
2.56
1 month 1.87
Extreme 1.87
2.65
Current year 1.8
Extreme 1.8
4.26
1 year 1.8
Extreme 1.8
5.87
3 years 0.86
Extreme 0.865
8.98
5 years 0.36
Extreme 0.36
8.98
10 years 0.36
Extreme 0.36
8.98
Manager TitleAgeSince
Chief Executive Officer - 11/10/2024
Chief Executive Officer - 01/01/2010
Director of Finance/CFO - 04/04/2022
Director TitleAgeSince
Chairman - 01/11/2013
Director/Board Member - 01/10/2010
Director/Board Member 72 29/03/2016
Date Insider Type Main position Quantity % Market Cap.
22/04/26 Sell

Chief Executive Officer

360,896 0.0969%
28/11/25 Free

Chairman

744,922 0.2003%
28/11/25 Free

Chief Executive Officer

301,906 0.0812%
Change 5-day change 1-year change 3-year change Capi.($)
-8.20%+1.29%-42.82%+168.57% 613M
+0.93%+6.97%+59.60%+68.35% 57.28B
-1.92%+6.03%+40.64%+83.42% 54.99B
-0.46%-1.29%+2.86%+428.78% 23.18B
-2.97%-2.35%-22.53%-16.40% 22.59B
-0.36%+5.73%+24.13%-6.24% 20.46B
-1.34%+0.51%+26.03%-29.41% 17.56B
-1.44%+5.67%+38.77%+504.71% 15.67B
-1.30%-5.02%+170.77%+291.37% 14.46B
-0.50%-0.98%+21.43%+180.07% 13.92B
Average -1.76%+1.28%+31.89%+167.32% 24.07B
Weighted average by Cap. -0.89%+2.09%+39.49%+133.58%

Financials

2026 *2027 *
Net sales - 933K 653K 573K 533K 489K 919K 62.85M 6.33M 2.47M 30.9M 2.45M 2.4M 107M
Net income -108M -75.49M -66.3M -61.66M -56.58M -106M -7.27B -732M -286M -3.57B -283M -277M -12.36B -121M -84.56M -74.27M -69.07M -63.38M -119M -8.14B -820M -320M -4B -317M -311M -13.84B
Net Debt -161M -113M -98.89M -91.96M -84.39M -159M -10.84B -1.09B -427M -5.33B -423M -414M -18.43B -49.5M -34.62M -30.4M -28.27M -25.94M -48.75M -3.33B -336M -131M -1.64B -130M -127M -5.67B
Logo Clarity Pharmaceuticals Ltd
Clarity Pharmaceuticals Ltd is an Australia-based clinical-stage radiopharmaceutical company. The Company is focused on developing targeted copper theranostics based on its SAR Technology Platform. It is progressing clinical trials with its approximately three key products, SARTATE, SAR-bisPSMA, and SAR-Bombesin. Its lead product, SAR-bisPSMA, is progressing through over three clinical trials: one theranostic trial (SECuRE) and two Phase III diagnostic trials (CLARIFY and AMPLIFY). SARTATE is developed for diagnosing, staging, and treating cancers that express somatostatin receptor 2 (SSTR2). SAR-bisPSMA is developed for diagnosing, staging, and treating prostate cancer that expresses prostate-specific membrane antigen (PSMA). SAR-Bombesin is developed for identifying and selecting patients for subsequent treatment of cancers that express a specific receptor called the gastrin releasing peptide receptor (GRPr), including breast cancer and prostate cancer.
Employees
88
Date Price Change Volume
24/07/26 A$2.350 -8.20% 2,294,721
23/07/26 A$2.560 +9.40% 2,911,546
22/07/26 A$2.340 +4.93% 1,802,014
21/07/26 A$2.230 -3.88% 2,368,760
20/07/26 A$2.320 0.00% 1,158,733
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.350AUD
Average target price
7.228AUD
Spread / Average Target
+207.55%

Annual profits - Rate of surprise